NxStage Medical (NXTM) Receives Media Impact Score of 0.19
News articles about NxStage Medical (NASDAQ:NXTM) have trended somewhat positive on Sunday, according to Accern Sentiment. The research group rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. NxStage Medical earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned media coverage about the medical device company an impact score of 46.1128372429892 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
A number of analysts have recently commented on the company. BidaskClub lowered NxStage Medical from a “buy” rating to a “hold” rating in a research note on Friday, July 20th. Zacks Investment Research lowered NxStage Medical from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, ValuEngine raised NxStage Medical from a “hold” rating to a “buy” rating in a research note on Friday, July 6th. One analyst has rated the stock with a sell rating and five have issued a hold rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $30.00.
Shares of NxStage Medical traded up $0.04, reaching $28.30, during mid-day trading on Friday, according to MarketBeat. 245,504 shares of the company were exchanged, compared to its average volume of 423,271. NxStage Medical has a 52 week low of $22.70 and a 52 week high of $29.39. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of -128.64 and a beta of 0.02.
NxStage Medical Company Profile
NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.
Further Reading: Diversification in Investing
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.